HIV-1; antiretroviral drug resistance; interpretation algorithm; line probe assay
Abstract :
[en] Background: Resistance testing is increasingly accepted as a tool in guiding the selection of human immunodeficiency virus type 1 (HIV-1) antiretroviral therapy in HIV-1 infected individuals who fail their current regimen. Objectives: To descriptively compare the correlation between virologic treatment response and results using three genotypic HIV-1 drug resistance interpretation systems: the VERSANT(R) HIV-1 Resistance Assay (LiPA) system and two sequence-based interpretation systems. Study design: Specimens from 213 HIV-1-infected subjects, either starting (n = 104) or switching to (n = 109) a regimen of three or four antiretroviral drugs, were collected retrospectively at baseline and after 3 months of uninterrupted therapy. The correlation between viral load change and the number of predicted active drugs in the treatment regimen was assessed. An interpretation algorithm was recently developed to process VERSANT(R) HIV-1 Resistance Assay (LiPA) data. The number of active drugs predicted using this algorithm was rank correlated with the viral load change over a 3-month treatment period. For comparison, a similar calculation was made using two sequence-based algorithms (REGA version 5.5 and VGI GuideLines(TM) Rules 4.0), both applied on the same sequences. Results: Statistically significant (p < 0.05) correlation coefficients for each of the three HIV-1 drug resistance interpretation systems were observed in the treatment-experienced subjects on a 3-drug regimen (-0.39, -0.38, and -0.42, respectively) as well as on a 4-drug regimen (-0.33, -0.31, and -0.37, respectively). However, no significant correlation was observed in treatment-naive subjects, probably due to the very low frequency of drug resistance in these subjects. Conclusion: All three genotypic drug resistance interpretation systems (LiPA version 1, REGA version 5.5, and VGI GuideLines(TM) Rules 4.0) were statistically significantly correlated with virologic therapy response as measured by viral load testing. (C) 2004 Elsevier B.V. All rights reserved.
Disciplines :
Immunology & infectious disease
Author, co-author :
Ziermann, Rainer
Celis, Linda
Derdelinckx, Inge
Lambert, Christine
Veeck, Jurgen
Rizzo, Maria G.
Vanderborght, Bart
Zissis, Georges
Clumeck, Nathan
Fransen, Katrien
Vaira, Dolorès ; Centre Hospitalier Universitaire de Liège - CHU > Immuno-hématologie
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
J.D. Baxter, D.L. Mayers, and D.N. Wentworth A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS AIDS 14 2000 F83 F93
C. Brites, F. Bahia, and M. Gilbert Evaluation of viral resistance to reverse transcriptase inhibitors (RTI) in HIV-1-infected patients before and after 6 months of single or double antiretroviral therapy Braz J Infect Dis 5 2001 177 182
L. Celis, J.C. Schmit, and S. Kaye Performance analysis of the VERSANT® HIV-1 RT Resistance Assay (LiPA) Proceedings of the 6th International Congress on Drug Therapy in HIV Infection Glasgow, UK, 17-21 November 2002 [Abstract]
P. Clevenbergh, J. Durant, and P. Halfon Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up Antivir Ther 5 2000 65 70
C. Cohen, S. Hunt, and M. Sension A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy AIDS 16 2002 579 588
A. De Luca, A. Cingolani, and S. Di Giambenedetto Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance J Infect Dis 187 2003 1934 1943
A. De Luca, A. Cingolani, and M.P. Trotta Prediction of virological and immunological outcomes by different interpretation systems for genotypic resistance in a cohort of highly active antiretroviral therapy-failed patients Antivir Ther 6 Suppl 1 2001 70
K. De Smet, L. Celis, and J.C. Schmit Identification of key mutations in the HIV-1 protease using the INNO-LiPA HIV protease assay Proceedings of the 2nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance Frankfurt, Germany, 25-27 February 2000 [Abstract 50]
J. Durant, P. Clevenbergh, and P. Halfon Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial Lancet 353 1999 2195 2199
M.S. Hirsch, F. Brun-Vezinet, and B. Clotet Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel Clin Infect Dis 37 2003 113 128
S.J. Little, S. Holte, and J.P. Routy Antiretroviral-drug resistance among patients recently infected with HIV N Engl J Med 347 2002 385 392
R.F. Schinazi, B.A. Larder, and J.W. Mellors Mutations in retroviral genes associated with drug resistance: 2001 update Int Antivir News 8 2000 65 91
M. Setti, B. Bruzzone, and F. Ansaldi Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART J Med Virol 64 2001 199 206
A. Tanuri, E. Caridea, and M.C. Dantas Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART J Clin Virol 25 2002 39 46
The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001;15:309-20.
C. Tural, L. Ruiz, and C. Holtzer Clinical utility of HIV-1 genotyping and expert advice: the Havana trial AIDS 16 2002 209 218
K. Van Laethem, A. De Luca, A. Antinori, C.F. Perno, and A.M. Vandamme A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients Antivir Ther 7 2002 123 129
K. Van Vaerenbergh, K. Van Laethem, and E. Van Wijngaerden Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy AIDS Res Hum Retroviruses 16 2000 529 537
A.M. Vandamme, F. Houyez, and D. Banhegyi Laboratory guidelines for the practical use of HIV resistance tests in patient follow-up Antivir Ther 6 2001 21 39
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
